SCHEMBL23545596

SCHEMBL23545596

CC(F)(F)c1ccc(CNC2CC2)cn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM1A O60341 2/20 0.47
▸ MAOA P21397 1/20 0.47
▸ MAOB P27338 1/20 0.47
▸ MEN1 O00255 1/20 0.41
▸ RAB9A P51151 1/20 0.41
▸ KMT2A Q03164 1/20 0.41
▸ KDM4E B2RXH2 1/20 0.40
▸ ALDH1A1 P00352 1/20 0.40
▸ PKM P14618 1/20 0.40
▸ HRH3 Q9Y5N1 2/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP3A5 P20815 1/20 0.39
▸ CXCR4 P61073 1/20 0.37
▸ POLB P06746 1/20 0.37
▸ CD274 Q9NZQ7 3/20 0.37
▸ BCHE P06276 1/20 0.36
▸ ACHE P22303 1/20 0.36
▸ BACE1 P56817 1/20 0.36
▸ AXL P30530 1/20 0.36
▸ FLT3 P36888 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30471873 1.00 KDM1A (0.47) KDM1AMAOAMAOBMEN1RAB9A
SCHEMBL19650812 0.88 KDM1A (0.59) KDM1AMAOAMAOBMEN1RAB9A
SCHEMBL22787427 0.85 KDM1A (0.47) KDM1AMAOAMAOBMEN1RAB9A
SCHEMBL22787431 0.85 KDM1A (0.41) KDM1AMAOAMAOBMEN1RAB9A
SCHEMBL30471890 0.82 KDM1A (0.56) KDM1AMAOAMAOBKDM4EALDH1A1
SCHEMBL23545538 0.82 KDM1A (0.56) KDM1AMAOAMAOBKDM4EALDH1A1
SCHEMBL22663449 0.79 KDM1A (0.40) KDM1AMAOAMAOBKDM4ECYP3A4
SCHEMBL21729631 0.76 ACHE (0.50) KDM1AMAOAMAOBMEN1RAB9A
SCHEMBL26944359 0.76 KDM4E (0.49) MEN1RAB9AKMT2AKDM4EALDH1A1
SCHEMBL12266677 0.73 KDM4E (0.41) KDM1AMAOAMAOBRAB9AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230271937-A1 COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS NUEVOLUTION A/S (DK) 2023-08-31 — — US disclosed
US-20230271937-A1 COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS NUEVOLUTION A/S (DK) 2023-08-31 — — US disclosed
US-11685727-B2 Compounds active towards nuclear receptors NUEVOLUTION A/S (DK) 2023-06-27 — — US disclosed
US-20210188807-A1 COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS ALMIRALL, S.A. (ES) 2021-06-24 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11685727-B2 Compounds active towards nuclear receptors NCOA1, NR1H2, NCOA3 KDM1A 4089/4885MAOA 3525/4885MAOB 3188/4885
US-20230271937-A1 COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS NCOA1, NR1H2, NCOA3 KDM1A 4089/4885MAOA 3525/4885MAOB 3188/4885
US-20210188807-A1 COMPOUNDS ACTIVE TOWARDS NUCLEAR RECEPTORS NCOA1, NR1H2, NCOA3 KDM1A 4089/4885MAOA 3525/4885MAOB 3188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback